Inhibikase Therapeutics (IKT) Other Gross PP&E Adjustments (2020 - 2025)
Historic Other Gross PP&E Adjustments for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $117224.0.
- Inhibikase Therapeutics' Other Gross PP&E Adjustments rose 50035.52% to $117224.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $117224.0, marking a year-over-year increase of 50035.52%. This contributed to the annual value of -$3.8 million for FY2024, which is 3746.77% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at $117224.0 for Q3 2025, which was up 50035.52% from $82306.0 recorded in Q2 2025.
- Inhibikase Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at $117224.0 during Q3 2025, with a 5-year trough of -$3.8 million in Q4 2024.
- In the last 5 years, Inhibikase Therapeutics' Other Gross PP&E Adjustments had a median value of -$86218.5 in 2021 and averaged -$744502.8.
- In the last 5 years, Inhibikase Therapeutics' Other Gross PP&E Adjustments crashed by 20581.66% in 2024 and then surged by 50035.52% in 2025.
- Inhibikase Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$2.3 million in 2021, then dropped by 11.14% to -$2.5 million in 2022, then decreased by 8.78% to -$2.7 million in 2023, then tumbled by 37.47% to -$3.8 million in 2024, then surged by 103.1% to $117224.0 in 2025.
- Its Other Gross PP&E Adjustments was $117224.0 in Q3 2025, compared to $82306.0 in Q2 2025 and $48505.0 in Q1 2025.